These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. Cyr JE; Pearson DA; Wilson DM; Nelson CA; Guaraldi M; Azure MT; Lister-James J; Dinkelborg LM; Dean RT J Med Chem; 2007 Mar; 50(6):1354-64. PubMed ID: 17315859 [TBL] [Abstract][Full Text] [Related]
26. Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. Di Cianni A; Carotenuto A; Brancaccio D; Novellino E; Reubi JC; Beetschen K; Papini AM; Ginanneschi M J Med Chem; 2010 Aug; 53(16):6188-97. PubMed ID: 20666484 [TBL] [Abstract][Full Text] [Related]
27. Gold nanoparticles conjugated to [Tyr3]octreotide peptide. Surujpaul PP; Gutiérrez-Wing C; Ocampo-García B; Ramírez Fde M; Arteaga de Murphy C; Pedraza-López M; Camacho-López MA; Ferro-Flores G Biophys Chem; 2008 Dec; 138(3):83-90. PubMed ID: 18819743 [TBL] [Abstract][Full Text] [Related]
28. Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration. Melis M; Valkema R; Krenning EP; de Jong M J Nucl Med; 2012 May; 53(5):749-53. PubMed ID: 22496587 [TBL] [Abstract][Full Text] [Related]
29. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940 [TBL] [Abstract][Full Text] [Related]
30. NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide. Deshmukh MV; Voll G; Kühlewein A; Mäcke H; Schmitt J; Kessler H; Gemmecker G J Med Chem; 2005 Mar; 48(5):1506-14. PubMed ID: 15743193 [TBL] [Abstract][Full Text] [Related]
31. A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells. Vaidyanathan G; Affleck DJ; Norman J; O'Dorisio S; Zalutsky MR Bioconjug Chem; 2007; 18(6):2122-30. PubMed ID: 17979223 [TBL] [Abstract][Full Text] [Related]
32. [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide. Stahl A; Meisetschläger G; Schottelius M; Bruus-Jensen K; Wolf I; Scheidhauer K; Schwaiger M Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):45-52. PubMed ID: 16151771 [TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789 [TBL] [Abstract][Full Text] [Related]
34. Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. Poethko T; Schottelius M; Thumshirn G; Hersel U; Herz M; Henriksen G; Kessler H; Schwaiger M; Wester HJ J Nucl Med; 2004 May; 45(5):892-902. PubMed ID: 15136641 [TBL] [Abstract][Full Text] [Related]
35. Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results. Valencak J; Heere-Ress E; Traub-Weidinger T; Raderer M; Schneeberger A; Thalhammer T; Aust S; Hamilton G; Virgolini I; Pehamberger H Melanoma Res; 2005 Dec; 15(6):523-9. PubMed ID: 16314738 [TBL] [Abstract][Full Text] [Related]
36. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. Ginj M; Hinni K; Tschumi S; Schulz S; Maecke HR J Nucl Med; 2005 Dec; 46(12):2097-103. PubMed ID: 16330576 [TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptors in malignant lymphomas: targets for radiotherapy? Dalm VA; Hofland LJ; Mooy CM; Waaijers MA; van Koetsveld PM; Langerak AW; Staal FT; van der Lely AJ; Lamberts SW; van Hagen MP J Nucl Med; 2004 Jan; 45(1):8-16. PubMed ID: 14734660 [TBL] [Abstract][Full Text] [Related]
38. A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting. Ghosh SC; Rodriguez M; Carmon KS; Voss J; Wilganowski NL; Schonbrunn A; Azhdarinia A J Nucl Med; 2017 Nov; 58(11):1858-1864. PubMed ID: 28572490 [TBL] [Abstract][Full Text] [Related]
39. Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Hofland LJ; Breeman WA; Krenning EP; de Jong M; Waaijers M; van Koetsveld PM; Mäcke HR; Lamberts SW Proc Assoc Am Physicians; 1999; 111(1):63-9. PubMed ID: 9893158 [TBL] [Abstract][Full Text] [Related]